Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Moderna, Inc. (NASDAQ ... Overall, MRNA ranks 5th on our list of Goldman Sachs' top growth investors. While we acknowledge the potential of MRNA as an investment, our conviction lies in the ...

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook.

Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to Neutral and lowers the price target from $99 to $51. The analyst expects Moderna to report product revenue at the low end of ...

Moderna's recent forecast for fiscal year 2025 respiratory vaccine business revenue is set between $1.5 billion and $2.5 billion, with Goldman Sachs estimating the lower end of this range.

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (XTRA:0QF) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna is ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (LSE:0A45) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna is ...

Goldman Sachs Group Inc. is embarking on its most ambitious effort yet to offer an exit ramp for investors trapped in buyout ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where ranks on the list. With the 2024 US ...